ARHGEF25

Summary

ARHGEF25 (Rho guanine nucleotide exchange factor 25, HGNC:30275) is a protein-coding gene on chromosome 12q13.3, encoding Rho guanine nucleotide exchange factor 25 (Q86VW2). May play a role in actin cytoskeleton reorganization in different tissues since its activation induces formation of actin stress fibers.

Rho GTPases alternate between an inactive GDP-bound state and an active GTP-bound state, and GEFs facilitate GDP/GTP exchange. This gene encodes a guanine nucleotide exchange factor (GEF) which interacts with Rho GTPases involved in contraction of vascular smooth muscles, regulation of responses to angiotensin II and lens cell differentiation. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 115557 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 105 total — 1 likely-pathogenic
• MANE Select transcript: NM_182947

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30275
Approved symbol	ARHGEF25
Name	Rho guanine nucleotide exchange factor 25
Location	12q13.3
Locus type	gene with protein product
Status	Approved
Aliases	GEFT, p63RhoGEF
Ensembl gene	ENSG00000240771
Ensembl biotype	protein_coding
OMIM	610215
Entrez	115557

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 4 retained_intron

ENST00000286494, ENST00000333972, ENST00000466399, ENST00000469072, ENST00000471370, ENST00000484357, ENST00000616622, ENST00000885360, ENST00000885361, ENST00000885362

RefSeq mRNA: 3 — MANE Select: NM_182947 NM_001111270, NM_001347933, NM_182947

CCDS: CCDS44931, CCDS8947

Canonical transcript exons

ENST00000286494 — 15 exons

Exon	Start	End
ENSE00001023864	57614516	57614605
ENSE00001023880	57614331	57614400
ENSE00001023885	57613694	57613760
ENSE00001023901	57614016	57614119
ENSE00001023908	57613440	57613516
ENSE00001598974	57613264	57613359
ENSE00001611343	57612930	57613144
ENSE00001747459	57611435	57611991
ENSE00003493656	57615237	57615314
ENSE00003516426	57616284	57616495
ENSE00003562851	57615512	57615712
ENSE00003602933	57615837	57616017
ENSE00003630204	57614967	57615017
ENSE00003690293	57614689	57614781
ENSE00003846392	57616784	57617245

Expression profiles

Bgee: expression breadth ubiquitous, 139 present calls, max score 98.64.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.1333 / max 431.9318, expressed in 1433 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
126296	16.3925	1385
126295	4.3852	1234
126297	0.9202	440
126293	0.2689	99
126291	0.1050	44
126292	0.0614	34

Top tissues by expression

139 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	98.64	gold quality
cerebellar hemisphere	UBERON:0002245	98.53	gold quality
cerebellar cortex	UBERON:0002129	98.52	gold quality
cerebellum	UBERON:0002037	98.51	gold quality
right coronary artery	UBERON:0001625	98.25	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.22	gold quality
lower esophagus	UBERON:0013473	98.20	gold quality
mucosa of stomach	UBERON:0001199	98.11	gold quality
body of uterus	UBERON:0009853	98.08	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.04	gold quality
popliteal artery	UBERON:0002250	98.01	gold quality
tibial artery	UBERON:0007610	98.01	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.96	gold quality
left uterine tube	UBERON:0001303	97.70	gold quality
myometrium	UBERON:0001296	97.68	gold quality
thoracic aorta	UBERON:0001515	97.37	gold quality
ascending aorta	UBERON:0001496	97.36	gold quality
right frontal lobe	UBERON:0002810	97.34	gold quality
left coronary artery	UBERON:0001626	97.25	gold quality
descending thoracic aorta	UBERON:0002345	97.19	gold quality
superior frontal gyrus	UBERON:0002661	96.97	gold quality
frontal cortex	UBERON:0001870	96.80	gold quality
frontal lobe	UBERON:0016525	96.79	gold quality
smooth muscle tissue	UBERON:0001135	96.74	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.42	gold quality
prefrontal cortex	UBERON:0000451	96.41	gold quality
cerebral cortex	UBERON:0000956	96.32	gold quality
Ammon’s horn	UBERON:0001954	96.20	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.11	gold quality
right ovary	UBERON:0002118	95.94	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.08

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 17)

• Results show that p63RhoGEF is a RhoA-specific GEF that may play a key role in actin cytoskeleton reorganization in different tissues, especially in heart cellular morphology. (PMID:11861769)
• GEFT enhances dendritic spine formation and neurite outgrowth in primary neurons and neuroblastoma cells, respectively, through the activation of Rac/Cdc42-PAK signaling pathways. (PMID:15322108)
• a new signaling pathway by which G alpha(q/11)-coupled receptors specifically induce Rho signaling through a direct interaction of activated G alpha(q/11) subunits with p63RhoGEF. (PMID:15632174)
• Endogenous GEFT is transcriptionally upregulated during myogenic differentiation and downregulated during adipogenic differentiation. (PMID:16314529)
• Together, our data provide new evidence suggesting that GEFT is an important regulator of multiple processes involved in axon and dendrite formation. (PMID:16496360)
• the crystal structure of the Galphaq-p63RhoGEF-RhoA complex, detailing the interactions of Galphaq with the Dbl and pleckstrin homology (DH and PH) domains of p63RhoGEF was determined (PMID:18096806)
• MLK3 functions in a regulated way to limit levels of the activated GTPase Rho by binding to the Rho activator, p63RhoGEF/GEFT, which, in turn, prevents its activation by Galphaq. (PMID:18851832)
• Specifically mediates angiotensin II- Gq/11-dependent RhoA activation and downstream signaling and processes in vascular smooth muscle cells (PMID:20739613)
• p63RhoGEF is regulated chiefly through allosteric control by Galpha(q), as opposed to other known Galpha-regulated RhoGEFs, which are instead sequestered in the cytoplasm, perhaps because of their high basal activity. (PMID:21832057)
• Signaling through p63RhoGEF provides a novel mechanism for selective regulation of blood pressure. (PMID:21885830)
• p63RhoGEF-mediated formation of a single polarized lamellipodium is required for chemotactic migration in breast carcinoma cells. (PMID:23380069)
• Signaling efficiency of Galphaq through its effectors p63RhoGEF and GEFT depends on their subcellular location. (PMID:23884432)
• assessed p63RhoGEF gene and protein expression and RhoA/Rho kinase activity in essential hypertensive and Bartter’s and Gitelman’s syndrome patients, a model opposite to hypertension (PMID:24356540)
• p63RhoGEF can rapidly activate RhoA through endogenous G-protein coupled receptors. (PMID:26435194)
• p63RhoGEF(619) relocates to the plasma membrane upon activation of Galphaq coupled GPCRs, resembling the well-known activation mechanism of RhoGEFs activated by Galpha12/13. (PMID:27833100)
• Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3beta-beta-catenin cascade via regulation of Rac1/Cdc42. (PMID:36977438)
• Lnc-PSMA8-1 activated by GEFT promotes rhabdomyosarcoma progression via upregulation of mTOR expression by sponging miR-144-3p. (PMID:38225540)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ARHGEF25	ENSDARG00000100606
mus_musculus	Arhgef25	ENSMUSG00000019467
rattus_norvegicus	Arhgef25	ENSRNOG00000005034

Paralogs (22): TRIO (ENSG00000038382), MCF2L2 (ENSG00000053524), PLEKHG2 (ENSG00000090924), MCF2 (ENSG00000101977), ARHGEF7 (ENSG00000102606), PLEKHG1 (ENSG00000120278), MCF2L (ENSG00000126217), ARHGEF6 (ENSG00000129675), ARHGEF9 (ENSG00000131089), VAV3 (ENSG00000134215), VAV1 (ENSG00000141968), TIAM2 (ENSG00000146426), KIAA1755 (ENSG00000149633), PLEKHG4B (ENSG00000153404), TIAM1 (ENSG00000156299), KALRN (ENSG00000160145), VAV2 (ENSG00000160293), ARHGEF40 (ENSG00000165801), SPATA13 (ENSG00000182957), SESTD1 (ENSG00000187231), PLEKHN1 (ENSG00000187583), PLEKHG4 (ENSG00000196155)

Protein

Protein identifiers

Rho guanine nucleotide exchange factor 25 — Q86VW2 (reviewed: Q86VW2)

Alternative names: Guanine nucleotide exchange factor GEFT, Rac/Cdc42/Rho exchange factor GEFT, RhoA/Rac/Cdc42 guanine nucleotide exchange factor GEFT, p63RhoGEF

All UniProt accessions (1): Q86VW2

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in actin cytoskeleton reorganization in different tissues since its activation induces formation of actin stress fibers. It works as a guanine nucleotide exchange factor for Rho family of small GTPases. Links specifically G alpha q/11-coupled receptors to RHOA activation. May be an important regulator of processes involved in axon and dendrite formation. In neurons seems to be an exchange factor primarily for RAC1. Involved in skeletal myogenesis.

Subunit / interactions. Interacts (via the DH domain) with POPDC1 (via the C-terminus cytoplasmic tail). Interacts with activated GNAQ and GNA11. Interacts with RHOA, CDC42 and RAC1.

Subcellular location. Cell membrane. Cytoplasm. Myofibril. Sarcomere.

Tissue specificity. Isoform 1 and isoform 2 are highly expressed in excitable tissues, such as brain, heart and muscle. Also detected in kidney and liver.

Domain organisation. The guanine nucleotide exchange activity is autoinhibited by the PH domain.

Isoforms (3)

UniProt ID	Names	Canonical?
Q86VW2-1	1	yes
Q86VW2-2	2, p63RhoGef
Q86VW2-3	3

RefSeq proteins (3): NP_001104740, NP_001334862, NP_891992* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000219	DH_dom	Domain
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR035899	DBL_dom_sf	Homologous_superfamily
IPR051336	RhoGEF_Guanine_NuclExch_SF	Family
IPR055251	SOS1_NGEF_PH	Domain

Pfam: PF00621, PF22697

UniProt features (55 total): helix 21, strand 9, mutagenesis site 6, region of interest 6, compositionally biased region 3, sequence variant 3, domain 2, splice variant 2, turn 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2RGN	X-RAY DIFFRACTION	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86VW2-F1	69.79	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (6):

Position	Phenotype
301	abolishes its exchange activity on rhoa.
471	reduces exchange activity mediated by gnaq activation; in truncated construct.
472	reduces exchange activity mediated by gnaq activation; in truncated construct.
475	reduces exchange activity mediated by gnaq activation; in truncated construct.
478	reduces exchange activity mediated by gnaq activation; in truncated construct.
479	reduces exchange activity mediated by gnaq activation; in truncated construct.

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-416476	G alpha (q) signalling events
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013026	RHOB GTPase cycle
R-HSA-9013106	RHOC GTPase cycle
R-HSA-9013148	CDC42 GTPase cycle
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-372790	Signaling by GPCR
R-HSA-388396	GPCR downstream signalling
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 85 (showing top): MODY_HIPPOCAMPUS_POSTNATAL, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_NEUROGENESIS, MARTINEZ_RB1_TARGETS_DN, GOBP_CELL_PROJECTION_ORGANIZATION, MODULE_207, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, MODULE_95, TGGAAA_NFAT_Q4_01, GOMF_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY, GOCC_EXTRINSIC_COMPONENT_OF_MEMBRANE, REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, MEISSNER_NPC_HCP_WITH_H3K4ME2

GO Biological Process (2): axon guidance (GO:0007411), regulation of small GTPase mediated signal transduction (GO:0051056)

GO Molecular Function (1): guanyl-nucleotide exchange factor activity (GO:0005085)

GO Cellular Component (7): cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), extrinsic component of membrane (GO:0019898), myofibril (GO:0030016), sarcomere (GO:0030017), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
RHO GTPase cycle	5
Signal Transduction	2
GPCR downstream signalling	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by GPCR	1
Signaling by Rho GTPases	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
membrane	2
axonogenesis	1
neuron projection guidance	1
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
intracellular anatomical structure	1
cytoplasm	1
cell periphery	1
contractile muscle fiber	1
myofibril	1

Protein interactions and networks

STRING

1330 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARHGEF25	GNAQ	P50148	948
ARHGEF25	RHOA	P06749	901
ARHGEF25	POPDC1	Q8NE79	776
ARHGEF25	RGS8	P57771	674
ARHGEF25	PAK5	Q9P286	669
ARHGEF25	RGS5	O15539	666
ARHGEF25	RGS21	Q2M5E4	666
ARHGEF25	RGS17	Q9UGC6	664
ARHGEF25	RGS20	O76081	660
ARHGEF25	CDC42	P21181	649
ARHGEF25	ARHGEF1	Q92888	645
ARHGEF25	RGS13	O14921	641
ARHGEF25	RGS11	O94810	640
ARHGEF25	RGS16	O15492	638
ARHGEF25	PLEK2	Q9NYT0	637
ARHGEF25	RGS12	O14924	637

IntAct

6 interactions, top by confidence:

A	B	Type	Score
LMO1	ZBTB43	psi-mi:“MI:0914”(association)	0.830
LMO3	ZBTB43	psi-mi:“MI:0914”(association)	0.550
RTN4R	SOAT1	psi-mi:“MI:0914”(association)	0.530
GABRB2	GABRB3	psi-mi:“MI:0914”(association)	0.350
CORO2B	SHC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (35): ARHGEF25 (Reconstituted Complex), ARHGEF25 (Affinity Capture-MS), ARHGEF25 (Affinity Capture-MS), ARHGEF25 (Affinity Capture-MS), RHOA (Biochemical Activity), ARHGEF25 (Reconstituted Complex), ARHGEF25 (FRET), ARPC1B (Affinity Capture-MS), CBX1 (Affinity Capture-MS), FAM207A (Affinity Capture-MS), PLEC (Affinity Capture-MS), C14orf166 (Affinity Capture-MS), CCDC86 (Affinity Capture-MS), DNAJC9 (Affinity Capture-MS), FLOT1 (Affinity Capture-MS)

ESM2 similar proteins: A2AB59, B1AK53, B2DD29, D3YZU1, D3ZG83, O09039, O14976, O54967, O75427, P80192, P98171, Q02779, Q17R13, Q3TBD2, Q3U1V8, Q3UHC7, Q4ACU6, Q4LDD4, Q5DU25, Q5JU85, Q5RB40, Q5RJI5, Q5TCX8, Q5U2X5, Q5VWQ8, Q61097, Q61210, Q66HA1, Q66L42, Q6TLK4, Q6ZUM4, Q80XI6, Q86VW2, Q8IVT5, Q8R0S2, Q8R5F8, Q8R5G7, Q8TDC3, Q8TE68, Q8WWN8

Diamond homologs: A2ASS6, A2CG49, A4IFM7, A8C984, A8WXF6, E9PT87, F1M0Z1, G4SLH0, O02827, O08875, O43293, O44997, O54784, O60229, O62305, O70150, O75962, O88764, O94768, O94806, P07313, P08414, P10911, P13234, P18652, P18653, P18654, P20689, P22216, P25323, P29294, P51812, P53355, P97924, Q00168, Q0KHT7, Q0KL02, Q14012, Q15139, Q15418

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
ARHGEF25	“up-regulates activity”	RHOA	“guanine nucleotide exchange factor”
ARHGEF25	up-regulates	CDC42	“guanine nucleotide exchange factor”
ARHGEF25	up-regulates	RAC1	“guanine nucleotide exchange factor”
ARHGEF25	up-regulates	RHOA	“guanine nucleotide exchange factor”
GNAQ	“up-regulates activity”	ARHGEF25	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

105 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	81
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
982196	NM_182947.4(ARHGEF25):c.1327C>T (p.Arg443Cys)	Likely pathogenic

SpliceAI

2624 predictions. Top by Δscore:

Variant	Effect	Δscore
12:57610680:GCCCG:G	donor_gain	1.0000
12:57612831:GC:G	donor_gain	1.0000
12:57612858:G:GT	donor_gain	1.0000
12:57612871:GACCC:G	donor_gain	1.0000
12:57613346:GAGA:G	donor_gain	1.0000
12:57613437:CA:C	acceptor_loss	1.0000
12:57613438:A:AG	acceptor_gain	1.0000
12:57613438:A:C	acceptor_loss	1.0000
12:57613439:G:GA	acceptor_gain	1.0000
12:57613439:GC:G	acceptor_gain	1.0000
12:57613439:GCC:G	acceptor_gain	1.0000
12:57613439:GCCA:G	acceptor_gain	1.0000
12:57613439:GCCAC:G	acceptor_gain	1.0000
12:57613510:GGA:G	donor_gain	1.0000
12:57613511:GA:G	donor_gain	1.0000
12:57613511:GAG:G	donor_gain	1.0000
12:57613512:AGTAT:A	donor_loss	1.0000
12:57613513:GTAT:G	donor_gain	1.0000
12:57613515:ATGT:A	donor_loss	1.0000
12:57613516:TGTAA:T	donor_loss	1.0000
12:57613517:G:C	donor_loss	1.0000
12:57613517:G:GG	donor_gain	1.0000
12:57613518:TAAGT:T	donor_loss	1.0000
12:57613758:G:GT	donor_gain	1.0000
12:57614116:GAGA:G	donor_gain	1.0000
12:57614118:GA:G	donor_gain	1.0000
12:57614120:G:GG	donor_gain	1.0000
12:57614142:C:G	donor_gain	1.0000
12:57614320:A:AG	acceptor_gain	1.0000
12:57614326:TCCA:T	acceptor_loss	1.0000

AlphaMissense

3747 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:57613711:T:C	L168P	1.000
12:57614744:C:A	P291H	1.000
12:57614751:G:C	Q293H	1.000
12:57614751:G:T	Q293H	1.000
12:57614753:G:C	R294P	1.000
12:57613720:C:T	T171I	0.999
12:57613723:A:T	E172V	0.999
12:57613744:T:C	L179S	0.999
12:57613744:T:G	L179W	0.999
12:57614080:T:A	V206E	0.999
12:57614082:T:C	F207L	0.999
12:57614084:T:A	F207L	0.999
12:57614084:T:G	F207L	0.999
12:57614086:G:A	G208E	0.999
12:57614090:T:A	N209K	0.999
12:57614090:T:G	N209K	0.999
12:57614109:T:A	W216R	0.999
12:57614109:T:C	W216R	0.999
12:57614390:T:C	F239S	0.999
12:57614543:T:C	Y252H	0.999
12:57614543:T:G	Y252D	0.999
12:57614546:T:C	C253R	0.999
12:57614547:G:A	C253Y	0.999
12:57614548:T:G	C253W	0.999
12:57614555:A:G	K256E	0.999
12:57614557:G:C	K256N	0.999
12:57614557:G:T	K256N	0.999
12:57614564:T:C	S259P	0.999
12:57614732:T:C	L287P	0.999
12:57614735:T:C	L288P	0.999

dbSNP variants (sampled 300 via entrez): RS1000145879 (12:57612184 A>C), RS1000168809 (12:57612686 A>G), RS1001249025 (12:57615947 C>A), RS1001378807 (12:57610282 G>A), RS1001697326 (12:57611812 G>A,T), RS1001808862 (12:57611575 C>A,T), RS1002032774 (12:57613335 G>A), RS1002452557 (12:57617044 C>A), RS1002700921 (12:57610468 G>A), RS1003050932 (12:57611608 A>G), RS1003326278 (12:57617628 T>G), RS1004731800 (12:57610868 G>A,T), RS1004802818 (12:57609660 T>C,G), RS1005061815 (12:57615123 G>A,C,T), RS1005233503 (12:57610512 G>A,C,T)

Disease associations

OMIM: gene MIM:610215 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (2): Familial prostate cancer (Orphanet:1331), Moyamoya angiopathy (Orphanet:477768)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006624_101	Systolic blood pressure	3.000000e-16
GCST007267_6	Systolic blood pressure	4.000000e-13

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
mercuric bromide	decreases expression, affects cotreatment	2
Estradiol	affects cotreatment, increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	affects expression, increases methylation	2
FR900359	affects phosphorylation	1
sodium arsenite	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Triiodothyronine	decreases expression	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer